JP2000511416A5 - - Google Patents

Download PDF

Info

Publication number
JP2000511416A5
JP2000511416A5 JP1997541828A JP54182897A JP2000511416A5 JP 2000511416 A5 JP2000511416 A5 JP 2000511416A5 JP 1997541828 A JP1997541828 A JP 1997541828A JP 54182897 A JP54182897 A JP 54182897A JP 2000511416 A5 JP2000511416 A5 JP 2000511416A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997541828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000511416A (ja
JP4750912B2 (ja
Filing date
Publication date
Priority claimed from GB9610967A external-priority patent/GB9610967D0/en
Application filed filed Critical
Publication of JP2000511416A publication Critical patent/JP2000511416A/ja
Publication of JP2000511416A5 publication Critical patent/JP2000511416A5/ja
Application granted granted Critical
Publication of JP4750912B2 publication Critical patent/JP4750912B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP54182897A 1996-05-24 1997-05-23 フィブロネクチンのed―bドメインに対する抗体、それらの構造及び用途 Expired - Lifetime JP4750912B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9610967A GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods
GB9610967.3 1996-05-24
PCT/GB1997/001412 WO1997045544A1 (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008204682A Division JP2009050261A (ja) 1996-05-24 2008-08-07 フィブロネクチンのed―bドメインに対する抗体、それらの構造及び用途

Publications (3)

Publication Number Publication Date
JP2000511416A JP2000511416A (ja) 2000-09-05
JP2000511416A5 true JP2000511416A5 (cg-RX-API-DMAC10.html) 2005-02-10
JP4750912B2 JP4750912B2 (ja) 2011-08-17

Family

ID=10794298

Family Applications (2)

Application Number Title Priority Date Filing Date
JP54182897A Expired - Lifetime JP4750912B2 (ja) 1996-05-24 1997-05-23 フィブロネクチンのed―bドメインに対する抗体、それらの構造及び用途
JP2008204682A Pending JP2009050261A (ja) 1996-05-24 2008-08-07 フィブロネクチンのed―bドメインに対する抗体、それらの構造及び用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008204682A Pending JP2009050261A (ja) 1996-05-24 2008-08-07 フィブロネクチンのed―bドメインに対する抗体、それらの構造及び用途

Country Status (28)

Country Link
US (3) US7273924B1 (cg-RX-API-DMAC10.html)
EP (1) EP0906426B1 (cg-RX-API-DMAC10.html)
JP (2) JP4750912B2 (cg-RX-API-DMAC10.html)
KR (2) KR100741452B1 (cg-RX-API-DMAC10.html)
CN (1) CN100447159C (cg-RX-API-DMAC10.html)
AT (1) ATE361364T1 (cg-RX-API-DMAC10.html)
AU (1) AU729081B2 (cg-RX-API-DMAC10.html)
BG (1) BG65138B1 (cg-RX-API-DMAC10.html)
BR (1) BR9709350B1 (cg-RX-API-DMAC10.html)
CA (1) CA2256308C (cg-RX-API-DMAC10.html)
CZ (1) CZ295531B6 (cg-RX-API-DMAC10.html)
DE (1) DE69737683T2 (cg-RX-API-DMAC10.html)
DK (1) DK0906426T3 (cg-RX-API-DMAC10.html)
EA (1) EA004329B1 (cg-RX-API-DMAC10.html)
ES (1) ES2286831T3 (cg-RX-API-DMAC10.html)
GB (1) GB9610967D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0200546A2 (cg-RX-API-DMAC10.html)
IL (2) IL127216A0 (cg-RX-API-DMAC10.html)
IS (1) IS2508B (cg-RX-API-DMAC10.html)
NO (1) NO324904B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ333083A (cg-RX-API-DMAC10.html)
PL (1) PL188557B1 (cg-RX-API-DMAC10.html)
PT (1) PT906426E (cg-RX-API-DMAC10.html)
SI (1) SI0906426T1 (cg-RX-API-DMAC10.html)
SK (1) SK285916B6 (cg-RX-API-DMAC10.html)
TR (1) TR199802416T2 (cg-RX-API-DMAC10.html)
UA (1) UA74129C2 (cg-RX-API-DMAC10.html)
WO (1) WO1997045544A1 (cg-RX-API-DMAC10.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2400622A1 (en) * 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
DE60122873T2 (de) 2000-05-09 2007-02-15 Greenville Hospital System Therapeutische porenbildende peptide
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
CN1246333C (zh) * 2000-09-07 2006-03-22 舍林股份公司 EDb-纤粘连蛋白结构域(II)的受体
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
WO2003055917A2 (en) 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
PL374386A1 (en) * 2002-03-11 2005-10-17 Philogen S.P.A. Selective targeting of tumor vasculature using antibody molecules
EP2281578A3 (en) 2002-07-15 2011-04-13 Board of Regents, The University of Texas System Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
KR20050119120A (ko) 2003-03-14 2005-12-20 와이어쓰 인간 ⅰl-21 수용체에 대한 항체 및 그것의 용도
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
JP2008514900A (ja) 2004-07-30 2008-05-08 アデザ・バイオメデイカル・コーポレイシヨン 疾病および他の状態のマーカーとしての癌胎児性フィブロネクチンならびに癌胎児性フィブロネクチンの検出のための方法
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1803814A1 (en) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
US8921304B2 (en) 2009-12-14 2014-12-30 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
AU2012268970B2 (en) 2011-06-15 2016-01-28 Navigo Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
US20150183846A1 (en) 2012-06-13 2015-07-02 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
EP3029065B1 (en) * 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ed-b domain of fibronectin and uses thereof
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH 新規なegfr結合タンパク質
AU2016293063B2 (en) 2015-07-16 2018-11-08 Navigo Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
EP3378947B1 (en) * 2015-11-16 2024-01-24 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
WO2018029158A1 (en) 2016-08-11 2018-02-15 Repligen Corporation Alkaline stable fc—binding proteins for affinity chromatography
WO2018073680A1 (en) 2016-10-17 2018-04-26 Pfizer Inc. Anti-edb antibodies and antibody-drug conjugates
CN110997718B (zh) 2017-06-07 2023-11-10 菲洛根股份公司 血管内皮生长因子/抗纤连蛋白抗体融合蛋白
CN117430699A (zh) 2017-09-30 2024-01-23 合肥立方制药股份有限公司 结合至纤维连接蛋白b结构域的蛋白
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
IL284097B2 (en) 2018-12-18 2025-10-01 Navigo Proteins Gmbh FOLR1-binding proteins for cancer diagnosis and treatment
EP4013783A1 (en) 2019-08-15 2022-06-22 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
JP2023506750A (ja) 2019-12-11 2023-02-20 シラグ・ゲーエムベーハー・インターナショナル Ltbr及びedb結合ドメインを含む多重特異性結合分子並びにその使用
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN118510535A (zh) 2022-01-04 2024-08-16 菲洛根股份公司 包含il-12的免疫细胞因子与激酶抑制剂的组合
EP4565277A1 (en) 2022-08-01 2025-06-11 Philochem AG Conjugates of psma-binding moieties with cytotoxic agents
CA3266566A1 (en) 2022-09-06 2024-03-14 Philochem Ag MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPH082308B2 (ja) 1985-01-28 1996-01-17 インタ−ナショナル・ジェネティック・エンジニアリング,インコ−ポレイテッド araBプロモーターを含有する複製可能な発現ビヒクル
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4894326A (en) 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) * 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
JPH02598A (ja) * 1987-10-09 1990-01-05 De La Rue Co Plc:The 集積回路カード
DE68926882T2 (de) 1988-01-11 1997-02-13 Xoma Corp Plasmidvektor mit pectatlyase-signalsequenz
IT1217724B (it) * 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5177015A (en) 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH0276598A (ja) 1988-09-14 1990-03-15 Fujita Gakuen 抗ed−b抗体
JPH04169195A (ja) 1990-10-31 1992-06-17 Fujita Gakuen 抗ed―bモノクローナル抗体
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
EP0614696A4 (en) 1992-09-25 1995-04-26 Otsuka Pharma Co Ltd ADSORBENT FOR CELLULAR FIBRONECTIN, SEPARATION AND PURIFICATION OF FIBRONECTIN, AND PURIFICATION OF BLOOD.
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6015897A (en) 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ITFI940095A1 (it) 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
WO1996023816A1 (en) 1995-02-01 1996-08-08 British Technology Group Limited Radiolabelled proteins
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
CA2400622A1 (en) 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US8623373B2 (en) 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
WO2003055917A2 (en) 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
JP4169195B2 (ja) * 2003-06-24 2008-10-22 株式会社河合楽器製作所 電子楽音発生装置の記録制御装置

Similar Documents

Publication Publication Date Title
JP2001504330A5 (cg-RX-API-DMAC10.html)
JP2000513471A5 (cg-RX-API-DMAC10.html)
JP2000501018A5 (cg-RX-API-DMAC10.html)
JP2000512783A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2002500504A5 (cg-RX-API-DMAC10.html)
JP2000501324A5 (cg-RX-API-DMAC10.html)
JP2000500055A5 (cg-RX-API-DMAC10.html)
JP2000500026A5 (cg-RX-API-DMAC10.html)
JP2001508473A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000511416A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2000515132A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2001503620A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000507828A5 (cg-RX-API-DMAC10.html)
JP2001501936A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000512095A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)